TNDM
Tandem Diabetes Care, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$19.90
−2.59%Year over year
Reported trailing growth
- Revenue
- -7.1%
- EBITDA
- +82.9%
- EBIT
- +78.4%
- EPS
- +69.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +9.2%
- EBITDA
- +207.6%
- EPS
- +77.2%
Three-year CAGR
- Revenue
- +8.2%
- EBITDA
- -76.2%
- EBIT
- +21.2%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026